Publications by authors named "Lu-Rong Pan"
Amyloid transthyretin (ATTR) amyloidosis caused by transthyretin misfolded into amyloid deposits in nerve and heart is a progressive rare disease. The unknown pathogenesis and the lack of therapy make the 5-year survival prognosis extremely poor. Currently available ATTR drugs can only relieve symptoms and slow down progression, but no drug has demonstrated curable effect for this disease.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the role of IgG -glycosylation in chronic thromboembolic pulmonary hypertension (CTEPH) to understand its inflammatory mechanisms and identify potential new markers and therapies.
- Researchers analyzed the plasma IgG -glycome in CTEPH patients, finding decreased IgG galactosylation associated with a proinflammatory state and strong connections to clinical markers like NT-proBNP.
- This groundbreaking research is the first to map the IgG -glycome's proinflammatory phenotype in CTEPH, highlighting its potential as an indicator of inflammation and enhancing our understanding of the disease's glycomic mechanisms.
Objectives: Hereditary transthyretin amyloidosis (ATTRv) is a rare, fatal, autosomal dominant disease with more than 140 mutations discovered. Three phenotypes of amyloid infiltration are neuropathy (ATTRv-PN), cardiopathy (ATTRv-CM), and neuropathy + cardiopathy (ATTRv-MIX). The lack of ATTR-specific biomarkers, difficulties in biopsy evidence, and limited known pathogenic mechanisms have made diagnosis difficult.
View Article and Find Full Text PDF